BEIGF:OTCMKTS
BeOne Medicines
21,95 USD
0,00%
(0,00) 1 D.
06-09, 12:49:46 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „BEIGF“ įžvalgos...
Rinkos kapitalizacija
44,07 mlrd.
Vid. kiekis
0,00
Apimtis
0,00
52 sav. aukšta
24,92 USD
52 sav. žema
21,95 USD
Beta
0,86
Neapmokėtos akcijos
1,43 mlrd.
Darbuotojų skaičius
12 tūkst.
Rinkos kapitalizacija
44,07 mlrd.
Vid. kiekis
0,00
Apimtis
0,00
52 sav. aukšta
24,92 USD
52 sav. žema
21,95 USD
Beta
0,86
Neapmokėtos akcijos
1,43 mlrd.
Darbuotojų skaičius
12 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Investing.com Canada
·
prieš 3 valandas
Form 144 BEONE MEDICINES LTD. For: 1 October By Investing.com
Investing.com Canada
·
prieš 5 valandas
Form 4 BeOne Medicines Ltd. For: 1 October By Investing.com
MarketBeat
·
prieš 12 valandų
BeOne Medicines (NASDAQ:ONC) Insider Sells $11,318,704.12 in Stock
Stock Titan
·
prieš 14 valandų
After exercising options, BeOne Medicines (ONC) scientific advisory chair sold 31,028 depositary shares.
Profilis
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Apie „BeOne Medicines“
Generalinis direktoriusJohn Vincent Oyler | John Vincent Oyler
Darbuotojai12 tūkst.
Įkurta2010-10-28
Pagrindinė būstinė-
Sektorius-
Svetainėbeonemedicines.com